Endovia Health Sciences, Inc. (EDVA) Stock Price
EDVAStock
$0.15
Market Cap$1.62M
P/E—
PEG Ratio—
Div yield—
Beta2.66
EDVA Share Price Chart
Favorite Metrics
Price vs S&P 500 (4W)-38.17%
VGM Score16.80
EDVA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q3 2024 | -$12.80 | -$11.90 | +7.00%(+$0.90) | |
| Q2 2024 | -$14.40 | -$17.60 | -22.22%(-$3.20) | |
| Q1 2024 | -$12.80 | -$16.00 | -25.00%(-$3.20) | |
| Q4 2023 | -$16.00 | -$20.80 | -30.00%(-$4.80) |
EDVA Analyst Recommendations
Apr 2025
May 2025
Jun 2025
Jul 2025
4.14
4.14
4.14
4.14
Industry Peers — Beverages(23)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
EDVAEndovia Health Sciences, Inc. | — | F | D | — | -237.2% | -52.4% | — | $0.15 |
| KOCoca-Cola Company | F | C | A | 30.8x | 43.0% | 7.8% | 3.1% | $93.90 |
| PEPPepsiCo, Inc. | C | C | C | 21.7x | 50.6% | 5.9% | 3.0% | $131.49 |
| DEODiageo plc | C | B | A | 30.0x | 33.2% | 9.1% | 2.8% | $95.11 |
| ABEVAMBEV S.A. | C | C | B | 16.7x | 18.1% | 8.6% | 7.6% | $3.29 |
| KDPKeurig Dr Pepper Inc. | D | C | A | 22.7x | 5.2% | 7.4% | 2.6% | $34.62 |
| STZConstellation Brands, Inc. | C | C | C | 13.2x | 23.6% | 1.2% | 1.5% | $131.35 |
| BF.ABrown-Forman Corporation Class A | D | D | B | 18.7x | 17.8% | 2.6% | 1.5% | $29.46 |
| BF.BBrown-Forman Corporation Class B | D | D | B | 18.7x | 17.8% | 2.6% | 1.5% | $28.88 |
| PRMBPrimo Brands Corporation | D | A | C | 118.8x | 3.3% | 27.8% | 2.0% | $19.72 |
| COCOThe Vita Coco Company, Inc. Common Stock | F | B | B | 47.2x | 31.1% | 14.4% | — | $58.69 |
About Endovia Health Sciences, Inc.
Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.